O	0	4	Real	Real	JJ	B-NP
O	5	9	time	time	NN	I-NP
O	10	12	RT	RT	NN	I-NP
O	12	13	-	-	HYPH	O
O	13	16	PCR	PCR	NN	B-NP

O	17	20	RNA	RNA	NN	B-NP
O	21	31	extraction	extraction	NN	I-NP
O	32	35	and	and	CC	O
O	36	40	real	real	JJ	B-NP
O	40	41	-	-	HYPH	I-NP
O	41	45	time	time	NN	I-NP
O	46	48	RT	RT	NN	I-NP
O	48	49	-	-	HYPH	B-NP
O	49	52	PCR	PCR	NN	I-NP
O	53	57	were	be	VBD	B-VP
O	58	67	performed	perform	VBN	I-VP
O	68	70	as	as	IN	B-SBAR
O	71	73	we	we	PRP	B-NP
O	74	83	described	describe	VBD	B-VP
O	84	94	previously	previously	RB	B-ADVP
O	95	96	[	[	(	O
O	96	98	22	22	CD	B-NP
O	98	99	]	]	)	O
O	99	100	.	.	.	O

O	101	104	The	The	DT	B-NP
O	105	114	sequences	sequence	NNS	I-NP
O	115	117	of	of	IN	B-PP
O	118	123	ABCG2	ABCG2	NN	B-NP
O	124	131	primers	primer	NNS	I-NP
O	132	135	are	be	VBP	B-VP
O	136	137	5	5	CD	B-NP
O	137	138	'	'	SYM	I-NP
O	138	139	-	-	HYPH	I-NP
O	139	169	GGCTTTCTACCTGCACGAAAACCAGTTGAG	GGCTTTCTACCTGCACGAAAACCAGTTGAG	NN	I-NP
O	169	170	-	-	HYPH	B-NP
O	170	171	3	3	CD	I-NP
O	171	172	'	'	SYM	B-NP
O	173	174	(	(	(	O
O	174	181	forward	forward	RB	B-ADVP
O	181	182	)	)	)	O
O	183	186	and	and	CC	O
O	187	188	5	5	CD	B-NP
O	188	189	'	'	SYM	I-NP
O	189	190	-	-	HYPH	I-NP
O	190	206	ATGGCGTTGAGACCAG	ATGGCGTTGAGACCAG	NN	I-NP
O	206	207	-	-	HYPH	B-NP
O	207	208	3	3	CD	I-NP
O	208	209	'	'	SYM	B-NP
O	210	211	(	(	(	O
O	211	218	reverse	reverse	NN	B-NP
O	218	219	)	)	)	O
O	219	220	.	.	.	O

O	221	224	The	The	DT	B-NP
O	225	234	sequences	sequence	NNS	I-NP
O	235	237	of	of	IN	B-PP
O	238	243	GAPDH	GAPDH	NN	B-NP
O	244	251	primers	primer	NNS	I-NP
O	252	255	are	be	VBP	B-VP
O	256	257	5	5	CD	B-NP
O	257	258	'	'	SYM	I-NP
O	258	259	-	-	HYPH	I-NP
O	259	282	AAGGACTCATGACCACAGTCCAT	AAGGACTCATGACCACAGTCCAT	NN	I-NP
O	282	283	-	-	HYPH	B-NP
O	283	284	3	3	CD	I-NP
O	284	285	'	'	SYM	B-NP
O	286	287	(	(	(	O
O	287	294	forward	forward	RB	B-ADVP
O	294	295	)	)	)	O
O	296	299	and	and	CC	O
O	300	301	5	5	CD	B-NP
O	301	302	'	'	SYM	I-NP
O	302	303	-	-	HYPH	I-NP
O	303	322	CCATCACGCCACAGTTTCC	CCATCACGCCACAGTTTCC	NN	I-NP
O	322	323	-	-	SYM	I-NP
O	323	324	3	3	CD	I-NP
O	324	325	'	'	SYM	B-NP
O	326	327	(	(	(	O
O	327	334	reverse	reverse	NN	B-NP
O	334	335	)	)	)	O
O	335	336	.	.	.	O

O	337	340	The	The	DT	B-NP
O	341	349	relative	relative	JJ	I-NP
O	350	355	ABCG2	ABCG2	NN	I-NP
O	356	359	RNA	RNA	NN	I-NP
O	360	365	level	level	NN	I-NP
O	366	367	(	(	(	O
O	367	375	2DeltaCT	2DeltaCT	NN	B-NP
O	375	376	)	)	)	O
O	377	384	treated	treat	VBN	B-VP
O	385	389	with	with	IN	B-PP
O	390	400	inhibitors	inhibitor	NNS	B-NP
O	401	404	was	be	VBD	B-VP
O	405	414	expressed	express	VBN	I-VP
O	415	417	as	as	IN	B-PP
O	418	428	percentage	percentage	NN	B-NP
O	429	431	of	of	IN	B-PP
O	432	435	the	the	DT	B-NP
O	436	443	control	control	NN	I-NP
O	444	445	(	(	(	O
O	445	447	in	in	IN	B-PP
O	448	451	the	the	DT	B-NP
O	452	460	presence	presence	NN	I-NP
O	461	463	of	of	IN	B-PP
O	464	465	0	0	CD	B-NP
O	465	466	.	.	.	O
O	466	467	1	1	CD	B-NP
O	467	468	%	%	NN	I-NP
O	469	473	DMSO	DMSO	NN	I-NP
O	473	474	)	)	)	O
O	475	480	where	where	WRB	B-ADVP
O	481	488	DeltaCT	DeltaCT	NN	B-NP
O	489	490	(	(	(	O
O	490	499	threshold	threshold	NN	B-NP
O	500	505	cycle	cycle	NN	I-NP
O	505	506	)	)	)	O
O	507	508	=	=	JJ	B-VP
O	509	510	(	(	(	O
O	510	517	CTABCG2	CTABCG2	NN	B-NP
O	517	518	-	-	HYPH	B-NP
O	518	525	CTGAPDH	CTGAPDH	NN	I-NP
O	525	526	)	)	)	O
O	526	527	.	.	.	O

